AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29158367 — intervention group
Group type: EXPERIMENTAL
Intervention: Necuparanib 5 mg/kg + nab-paclitaxel + gemcitabine
Number of subjects: 39
Study 29158367 — intervention group
Group type: EXPERIMENTAL
Intervention: Necuparanib 6 mg/kg + nab-paclitaxel + gemcitabine
Number of subjects: 39
Study 29158421 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy in urban hospitals (2001: 54%, 2011: not specified)
Number of subjects: 0
Study 29158421 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy in rural hospitals (2001: 57%, 2011: not specified)
Number of subjects: 0
Study 29158582 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs2709370
Number of subjects: 11105
Study 29158582 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs6785
Number of subjects: 11105
Study 29158678 — intervention group
Group type: EXPERIMENTAL
Intervention: DFN-15 120 mg
Number of subjects: 63
Study 29158678 — intervention group
Group type: EXPERIMENTAL
Intervention: DFN-15 240 mg
Number of subjects: 63
Study 29158678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 29158913 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based family-oriented treatment for peripartum depression
Number of subjects: 12
Study 29158913 — intervention group
Group type: COMPARATOR
Intervention: Historical comparison group of previously enrolled adolescent mothers
Number of subjects: 12
Study 29158914 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised progressive strength training intervention monitored by BandCizer
Number of subjects: 15
Study 29159083 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg BID
Number of subjects: 0
Study 29159083 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 150 mg BID
Number of subjects: 0
Study 29159083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29159204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 71
Study 29159204 — intervention group
Group type: COMPARATOR
Intervention: Nonpegylated interferon (IFN)
Number of subjects: 71
Study 29159457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 468
Study 29159457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 468
Study 29159457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 29159457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 468
Study 29159458 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg/week
Number of subjects: 25
Study 29159458 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 4.0 mg/kg/week
Number of subjects: 25
Study 29159458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dosage groups (2.0 mg/kg/week and 4.0 mg/kg/week)
Number of subjects: 25
Study 29159476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) administered as part of the FOLFOX regimen
Number of subjects: 0
Study 29159476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) dosage per kg lean body mass (LBM)
Number of subjects: 0
Study 29159476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) dosage for hematological toxicities
Number of subjects: 0
Study 29159476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 0
Study 29159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded autologous bone marrow-derived mesenchymal stem cells (MSCs)
Number of subjects: 3
Study 29159905 — intervention group
Group type: COMPARATOR
Intervention: Islet autotransplantation
Number of subjects: 3
Study 29160240 — intervention group
Group type: EXPERIMENTAL
Intervention: ECoG-based BCI system using somatotopic control strategy; subjects trained to control BCI by modulating high-gamma activity from attempted arm and hand movements for less than 30 days.
Number of subjects: 3
Study 29160240 — intervention group
Group type: EXPERIMENTAL
Intervention: ECoG-based BCI system with electrode coverage of somatosensory cortex.
Number of subjects: 3
Study 29160301 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram/Escitalopram treatment
Number of subjects: 2147
Study 29160421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparous women
Number of subjects: 120
Study 29160421 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 120
Study 29161241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (66.50 mg '4-weeks on/2-weeks off' schedule and 37.5 mg continuous daily dosing)
Number of subjects: 237
Study 29161241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg continuous daily dosing)
Number of subjects: 237
Study 29161241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 29161241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (general)
Number of subjects: 237
Study 29161279 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) on cfDNA
Number of subjects: 32
Study 29161279 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Number of subjects: 32
Study 29161802 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course CCRT
Number of subjects: 300
Study 29161802 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course CCRT
Number of subjects: 300
Study 29161802 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery timing < 6 weeks)
Number of subjects: 300
Study 29161802 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery timing 6-7 weeks)
Number of subjects: 300
Study 29162063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgE
Number of subjects: 101
Study 29162063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgG
Number of subjects: 101
Study 29162063 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 T-cell count <100 cells/μl
Number of subjects: 101
Study 29162063 — intervention group
Group type: EXPERIMENTAL
Intervention: Not on anti-retroviral therapy at baseline
Number of subjects: 101
Study 29162063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary x-ray findings
Number of subjects: 101
Study 29162085 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with LUTS
Number of subjects: 8284
Study 29162085 — intervention group
Group type: COMPARATOR
Intervention: Individuals without LUTS
Number of subjects: 8284
Study 29162085 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with LUTS (all three ICS symptom groups)
Number of subjects: 8284
Study 29162085 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing OAB severity
Number of subjects: 8284
Study 29162134 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (C1D1 for four 28-day cycles)
Number of subjects: 0
Study 29162134 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole monotherapy
Number of subjects: 0
Study 29162134 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib-induced decrease in serum TK1
Number of subjects: 0
Study 29162138 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided intraarticular facet joint infiltration
Number of subjects: 50
Study 29162138 — intervention group
Group type: COMPARATOR
Intervention: MRI features assessed (neuroforaminal stenosis grading, posterior disc height)
Number of subjects: 50
Study 29162148 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (15 one-directional health educative text messages and SMS reminders for their appointment over 10 months)
Number of subjects: 700
Study 29162148 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 700
Study 29162148 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 700
Study 29162340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm (systolic BP target of <120 mmHg)
Number of subjects: 9361
Study 29162340 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (systolic BP target of <140 mmHg)
Number of subjects: 9361
Study 29162343 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 176
Study 29162502 — intervention group
Group type: EXPERIMENTAL
Intervention: real rTMS (n=13)
Number of subjects: 28
Study 29162502 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS (n=15)
Number of subjects: 28
Study 29162557 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based telemonitoring system in addition to usual care
Number of subjects: 146
Study 29162557 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 29162610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Number of subjects: 607
Study 29162610 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic Diameter Stenosis (DS)
Number of subjects: 607
Study 29162610 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel-oriented clinical end point (VOCE)
Number of subjects: 607
Study 29162718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone hydrofluoroalkane inhaled via pMDI with no delay between shaking and actuation
Number of subjects: 0
Study 29162718 — intervention group
Group type: COMPARATOR
Intervention: In vitro + transport samples with no delay between shaking and actuation
Number of subjects: 0
Study 29162718 — intervention group
Group type: EXPERIMENTAL
Intervention: Delays between shaking and actuating the pMDI
Number of subjects: 0
Study 29162997 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer's knowledge of smoking and perceived negative impact of smoking on the company
Number of subjects: 100
Study 29162997 — intervention group
Group type: EXPERIMENTAL
Intervention: Company characteristics (white-collar vs. blue-collar)
Number of subjects: 100
Study 29162997 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace smoke-free policy and perceived responsibility
Number of subjects: 100
Study 29163136 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training (non-action video games) for 16 sessions
Number of subjects: 75
Study 29163136 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 75
Study 29163840 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 49
Study 29164129 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 0
Study 29164130 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative rehabilitation protocol (Gr2)
Number of subjects: 67
Study 29164130 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation protocol (Gr1)
Number of subjects: 67
Study 29164179 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth physiotherapeutic scoliosis-specific exercises (PSSE) + standard of care
Number of subjects: 50
Study 29164179 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50
Study 29164334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (1 µg/kg) test before extubation
Number of subjects: 80
Study 29164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive BRCA1/2 testing with written pre-test information and optional telephone genetic counseling
Number of subjects: 818
Study 29164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Written pre-test information
Number of subjects: 818
Study 29164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined process of pre-test information and genetic testing
Number of subjects: 818
Study 29165227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA)
Number of subjects: 0
Study 29165789 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPABLE program
Number of subjects: 204
Study 29165789 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison group
Number of subjects: 204
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month follow-up referral
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month functional disability (GOSE ≤ 6)
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pathology on ED head CT
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnesia (>30-minutes)
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnesia (unknown duration)
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (per-year)
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time/unemployment
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS < 15
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of seizures
Number of subjects: 168
Study 29166203 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased education (per-year)
Number of subjects: 168
Study 29166877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with above median extracellular volume (ECV) on cardiac magnetic resonance (CMR) imaging
Number of subjects: 0
Study 29166877 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ECV on CMR
Number of subjects: 0
Study 29166877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing surgery
Number of subjects: 0
Study 29166877 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic MR cohort
Number of subjects: 0
Study 29166878 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microRNAs and SNPs analysis in a case-control study
Number of subjects: 21000
Study 29166878 — intervention group
Group type: COMPARATOR
Intervention: Standard screening protocol
Number of subjects: 21000
Study 29166901 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen prescription
Number of subjects: 194
Study 29166901 — intervention group
Group type: COMPARATOR
Intervention: UCSD dyspnea scores
Number of subjects: 194
Study 29167092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling, manual therapy, and exercise
Number of subjects: 76
Study 29167092 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling, manual therapy, and exercise
Number of subjects: 76
Study 29167192 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0
Study 29167192 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 29167744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentive scheme for active travel to school (ATS); parents report ATS days via paper or SMS for a chance to win a £5 voucher
Number of subjects: 0
Study 29167744 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry (ActiGraph GT3X+) to monitor physical activity levels
Number of subjects: 0
Study 29167744 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily parental ATS reports
Number of subjects: 0
Study 29167745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention using smartphones for nutrition and physical activity
Number of subjects: 40
Study 29168107 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 107
Study 29168229 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29169258 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT (high-sensitivity cardiac troponin T)
Number of subjects: 273
Study 29169258 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI (high-sensitivity cardiac troponin I)
Number of subjects: 273
Study 29169258 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn assays
Number of subjects: 273
Study 29169258 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn concentrations in patients <60 years and ≥60 years
Number of subjects: 273
Study 29169394 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (steps per day)
Number of subjects: 194
Study 29169394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 194
Study 29169396 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) diet for 16 weeks
Number of subjects: 120
Study 29169396 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA) diet for 16 weeks
Number of subjects: 120
Study 29169396 — intervention group
Group type: COMPARATOR
Intervention: n-6 polyunsaturated fatty acids (PUFA) diet for 16 weeks
Number of subjects: 120
Study 29169399 — intervention group
Group type: EXPERIMENTAL
Intervention: PReDicT Test guided treatment
Number of subjects: 100
Study 29169399 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 100
Study 29169470 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved alternative anticoagulation (argatroban, lepirudin, danaparoid)
Number of subjects: 195
Study 29169470 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 195
Study 29169470 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved alternative anticoagulation
Number of subjects: 195
Study 29169474 — intervention group
Group type: COMPARATOR
Intervention: Early cohort (1990-1999)
Number of subjects: 1953
Study 29169474 — intervention group
Group type: EXPERIMENTAL
Intervention: Late cohort (2000-2009)
Number of subjects: 1953
Study 29169474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 1953
Study 29170088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites)
Number of subjects: 406
Study 29170358 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital heart diseases (CHD)
Number of subjects: 496
Study 29170358 — intervention group
Group type: COMPARATOR
Intervention: Age-adjusted and gender-adjusted controls
Number of subjects: 496
Study 29171941 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cellular therapy (ELAD) plus standard of care (SOC) for 3-5 days
Number of subjects: 203
Study 29171941 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 203
Study 29171941 — intervention group
Group type: EXPERIMENTAL
Intervention: ELAD
Number of subjects: 203
Study 29173296 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 737
Study 29173296 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 737
Study 29173296 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) and Body Mass Index (BMI)
Number of subjects: 737
Study 29173296 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) and Waist Circumference (WC)
Number of subjects: 737
Study 29173893 — intervention group
Group type: EXPERIMENTAL
Intervention: FoodforCare (FfC) meal service
Number of subjects: 637
Study 29173893 — intervention group
Group type: COMPARATOR
Intervention: Traditional meal service (TMS)
Number of subjects: 637
Study 29174300 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390
Study 29174484 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment for 1 year or longer
Number of subjects: 440
Study 29174484 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 440
Study 29174484 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoid treatment or cumulative treatment duration of less than 1 month
Number of subjects: 440
Study 29174484 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 440
Study 29174546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir (90 mg ledipasvir + 400 mg sofosbuvir, once daily for 12 weeks)
Number of subjects: 111
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculosis treatment
Number of subjects: 266
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started during the first month of follow-up
Number of subjects: 266
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed tuberculosis
Number of subjects: 266
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age
Number of subjects: 266
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 less than 10%
Number of subjects: 266
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: Miliary features
Number of subjects: 266
Study 29174612 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum transaminases
Number of subjects: 266
Study 29174789 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical strategy
Number of subjects: 1658
Study 29174789 — intervention group
Group type: COMPARATOR
Intervention: Location-based strategy
Number of subjects: 1658
Study 29174789 — intervention group
Group type: COMPARATOR
Intervention: Simplified optical strategy
Number of subjects: 1658
Study 29174789 — intervention group
Group type: COMPARATOR
Intervention: Simplified or location-based strategy
Number of subjects: 1658
Study 29174927 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography (CTC)
Number of subjects: 231
Study 29174927 — intervention group
Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 231
Study 29174939 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based screening and physician feedback algorithm
Number of subjects: 2038
Study 29175885 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Herts community physical activity programme including behaviour change technique booklet, regular consultations, booster phone call, motivational text messages, and signposting to 12 weeks of exercise classes.
Number of subjects: 0
Study 29175885 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Herts community physical activity programme with additional 12 weeks of free tailored exercise classes and optional exercise 'buddies'.
Number of subjects: 0
Study 29175898 — intervention group
Group type: EXPERIMENTAL
Intervention: LGMD2N cohort with known mutations and novel mutations
Number of subjects: 12
Study 29176494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) dosing between birth and 6 months (average 1882 LU/kg per meal, range: 492-3727)
Number of subjects: 205